Sarepta Therapeutics (NASDAQ: SRPT) saw its stock surge 8.79% in a 24-hour period, following the release of its second-quarter financial results that significantly exceeded analyst expectations. The biopharmaceutical company, known for its gene therapy and RNA-targeted approaches for rare diseases, delivered a stellar performance that impressed investors.
The company reported adjusted earnings per share (EPS) of $2.02 for Q2, dramatically surpassing the analyst consensus estimate of $0.67 by 201.49%. This represents a remarkable 369.77% increase from the $0.43 per share reported in the same period last year. Sarepta's quarterly sales also outperformed, coming in at $611.091 million and beating the analyst consensus estimate of $528.390 million by 15.65%. This figure marks a substantial 68.38% year-over-year increase from $362.931 million.
Adding to the positive sentiment, Sarepta announced that its Q2 2025 net product revenues totaled $513.1 million. The company also stated it is on track to realize over $100 million in cost savings through the end of 2025, demonstrating effective cost management alongside strong growth. These impressive results, showcasing both top-line growth and bottom-line improvement, likely fueled investor enthusiasm and drove the stock's significant rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.